US Edition
BMO Stands Firm on Tourmaline Bio (TRML) Amid Market Panic
Summary by Trading Tips
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
BMO Stands Firm on Tourmaline Bio (TRML) Amid Market Panic
BMO Capital Markets has reaffirmed their rating and price target on Tourmaline Bio (TRML), stating that the market has overreacted to recent news. This comes after TRML’s stock price dropped by over 10% in response to the company’s announcement of a secondary public offering. Despite the temporary dip in stock price, BMO maintains their Outperform rating on TRML, with a price target of $35 per share. The company’s recent public offering is expec…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
